Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban-Reference-Cited by-同舟云学术

Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban

Published:2016-04-27 Issue:1 Volume:3 Page:
ISSN:2054-9369
Container-title:Military Medical Research
language:en
Short-container-title:Military Med Res

Author:

Zhao Xin,Yang Xiao-Xu,Ji Su-Zhen,Wang Xiao-Zeng,Wang Li,Gu Chong-Huai,Ren Li-Li,Han Ya-Ling

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s40779-016-0081-6

Reference24 articles.

1. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases, part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746–53.

2. Popma JJ, Ohman EM, Weitz J, Lincoff AM, Hamrrington RA, Berger P, et al. Antiplatelet therapy in patients undergoing percutaneous coronary inter-vention. Chest. 2001;119:321S–36.

3. Smith Jr SC, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, et al. ACC/AHAguidelines for percutaneous coronary intervention: a report of theAmerican College of Cardiology/American Heart Association TaskForce on Practice Guidelines (Committee to Revise the 1993Guidelines for Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol. 2001;37:2215–39.

4. Steinbuhl SR, Talley JD, Braden GA, Tchena JE, Casterella PJ, Moliterno DJ, et al. Point-of-care measuredplatelet inhibition correlates with a reduced risk of an adverse cardiacevent after percutaneous coronary intervention: results of the GOLD (AU-assessing Ultegra) multicenter study. Circulation. 2001;103:2572–8.

5. Kandzari DE, Hasselblad V, Tcheng JE, Stone GW, Califf RM, Kastrati A, et al. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Am Heart J. 2004;147:457–62.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A study of anticoagulant therapy in patients with coronary artery disease;Journal of Basic and Clinical Physiology and Pharmacology;2021-06-25

2. Docosahexaenoic acid (DHA) inhibits pro-angiogenic effects of breast cancer cells via down-regulating cellular and exosomal expression of angiogenic genes and microRNAs;Life Sciences;2020-10

3. Traditional Chinese Medicine in Oncotherapy: The Research Status;Nutrition and Cancer;2019-09-17

4. Choosing between Enoxaparin and Fondaparinux for the management of patients with acute coronary syndrome: A systematic review and meta-analysis;BMC Cardiovascular Disorders;2017-05-08